Faculty
SELF-INTRODUCTION：
Yijin Wang, Ph.D., Associate Professor in the School of Medicine, Southern University of Science and Technology. After got the Master degree at Wageningen University and Research Center, the Netherlands, Yijin Wang moved to the Laboratory of Gastroenterology and Hepatology, Erasmus MC for her PhD research on Hepatitis E. She was concentrated on development of the anti-HEV therapies on the basis of understanding viral-host interaction. In addition to a list of publications, her discovery of potent antiviral activity by plants led to a Erasmus MC grant and harbour promising candidate for economical, less side-effect, complete anti-HEV therapy. Shortly after dissertation of PhD thesis in 2016, she started to establish her own research group at Department of Pathology and Hepatology, the 5thMedical Centre, Chinese people’s Liberation Army General Hospital, the best-known hospital specialized in infectious and liver diseases in China. As a young principal investigator, she supervised over 10 researchers. She has expended her research field to clinical and translational research of hepatitis B, C and E, SARS-CoV-2, as well as non-infectious liver diseases (NAFLD, HCC, ICC). By incorporating state-of-the-art molecular and cell biology, as well as abundant of patients specimen source, her research aims to contribute to the understanding of viral infection courses, virus-host interactions, mechanism of HEV activating and escaping innate immunity, to the development of new antiviral therapies and to resolving the clinical practical challenges. Dr. Wang’ group is already internationally well-recognized leader in respect of hepatitis E with significant contribution on viral infection biology, pathogenesis, and the development of accessible and effective antiviral therapy. Based on the research on infectious diseases, Dr. Wang also dedicated to elucidate novel mechanism of innate immune response. Her research has been supported by several (personal) grants, including “Science and Technology New Star" of BeiJing of 2019, National Natural Science Foundation of China, Innovative talent project of PLA General Hospital. She published 18 first /corresponding authorships of in total about 40 publications in peer-reviewed international journal with total IF>350, cited over 6000 times and edited an English language monograph.
EDUCATION:
2012 – 2016: PhD Degree, Department of Gastroenterology and Hepatology, Erasmus MC- University Medical Center Rotterdam, The Netherlands
2010 – 2012: Master degree, Wageningen University and Research Center, the Netherlands
2006- 2010: Bachelor degree, Nanjing Medical University, China
WOKRING EXPERIENCE:
11-2020 –： Associate professor, PI, at School of Medicine, Southern University of Science and Technology
11-2016 – 10-2020: Associate research fellow, PI, at Department of Pathology and Hepatology, the 5thMedical Centre, Chinese people’s Liberation Army General Hospital
HONORS AND AWARDS:
2021, Chinese medical science and Technology Award,third award
2020, Travel grant, from Asian Pacific Association for the Study of the Liver (APASL)
2019, Beijing science and technology new star, from Beijing Science and Technology Commission
2019, Innovative talent, from Chinese PLA hospital
2019, Young Investigator Bursary of International Liver Congress, from European Association for the Study of the Liver (EASL), (€ 650)
2018, Young Investigator Bursary of International Liver Congress, from European Association for the Study of the Liver (EASL), (€ 650)
2018, Young Investigator of Asia Pacific Annual meeting of Hepatology, from Asian Pacific Association for the Study of the Liver (APASL), ($ 800)
2017, Veldhovenbeurs Prize of Netherlands Annual meeting of Hepatology, from NVGE
2014, Young Investigator Bursary of International Liver Congress, from European Association for the Study of the Liver (EASL), (€ 650)
Research:
Understanding pathogenesis of hepatitis E on the basis of HEV viral infection courses, viral-host interaction, mechanisms of HEV activating and escaping innate immunity, and the antagonism to IFN therapy.
Development of potential economical, less side-effect anti-HEV strategy. Resolving the clinical practical challenges of hepatitis E, including diagnosis, diseases courses in distinct populations, prognosis and extra-hepatic manifestation.
Elucidating novel mechanism of innate immune response，particularly based on nucleotide synthesis inhibition, mitochondrial function.
Non-invasive diagnosis for severe non-infectious liver diseases, such as NAFLD, ICC
PUBLICATIONS：
1. Zhou H#, Dai Z#, Li J, Wang J, Zhu H, Chang X, Wang Y*. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury. Metabolism. 2023; 140:155383. (Corresponding Author)
2. Zhu H#, Dai Z#, Liu X#, Zhou H, Wang Y*. Serine/threonine kinase 3 promotes oxidative stress and mitochondrial damage in septic cardiomyopathy through inducing Kelch-like ECH-associated protein 1 phosphorylation and nuclear factor erythroid 2-related factor 2 degradation. Int J Biol Sci. 2023 (Corresponding Author)
3. Li R#, Dai Z#, Liu X#, Wang C, Huang J, Xin T, Tong Y, Wang Y*. Interaction between dual specificity phosphatase-1 and cullin-1 attenuates alcohol-related liver disease by restoring p62-mediated mitophagy. Int J Biol Sci. 2023 (Corresponding Author)
4. Wang C, Wang Y*. The role and mechanism of action of mitophagy in various liver diseases. Antioxid Redox Signal. 2022. (Corresponding Author)
5. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, et al. Wang Y*, Pan Q*. Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022; 75:196-212. (Co-Corresponding Author)
6. Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)
7. Wang Y#, Liu S#, Liu H#, Li W#, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.
8. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.Gastroenterology. 2014; 146:1775-83.
9. Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.
10. Li P, Li Y, Wang Y*, Liu J, Lavrijsen M, Li Y, et al. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022; 8:eabj5908. (Co-corresponding Author)
11. Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.
12. Wang Y#*, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30.
13. Wang Y#*, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300.
14. Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)
15. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.
16. Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.
17. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.
18. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31. (Corresponding Author)
19. Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.
20. Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. Dig Liver Dis. 2020; 52:637-43. (Co-First Author)
21. Wang J#, Huang A#, Wang Y#, Ji D, Liang Q, Zhao J, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial. Alimentary Pharmacology & Therapeutics. 2022; Accepted. (Co-First Author)
22. Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5. (Co-First Author)
23. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.
24. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.
25. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.
26. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.
27. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.
28. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.
29. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.
30. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.
31. Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.
32. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.
33. Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.
34. Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.
35. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.
36. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.
37. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.
38. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.
39. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.
40. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.
41. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.
42. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.
43. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.
44. Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.